,

Giredestrant: 10 Key Facts on the New Oral Treatment for ESR1-Mutated Breast Cancer

FDA approval of giredestrant (Wilserdly) plus everolimus on 16 November 2026: who it’s for, ESR1 mutation testing, evERA trial results, side effects and what it means for people with advanced breast cancer.

·

·

8–13 minutes

·

Edited by Joshua Adebanjo, RN

Giredestrant: New Pill for Advanced Breast Cancer

The US Food and Drug Administration (FDA) has approved giredestrant, sold as Wilserdly, taken by mouth together with everolimus, for some people with advanced breast cancer whose tumours carry a change in the ESR1 gene.

The approval, granted on 16 November 2026, covers adults with oestrogen receptor (ER)-positive, HER2-negative, ESR1-mutated breast cancer that is locally advanced or has spread, and has come back during or after hormone (endocrine) therapy. In the evERA Breast Cancer trial, people with ESR1 mutations who received giredestrant plus everolimus lived a median of 10 months without their cancer growing, compared with 5.5 months on standard hormone therapy plus everolimus. The FDA also authorised a blood test to find ESR1 mutations, and approved the application four weeks ahead of schedule.

giredestrant

Imagine a 57-year-old accountant in Canada who was treated for early breast cancer five years ago. Now scans show the cancer has spread to her bones. She has been taking hormone therapy, but it has stopped working. Her oncology nurse explains that a blood test can look for a change in a gene called ESR1, which often develops after hormone therapy and helps the cancer resist treatment. The test is positive. Her team discusses a newly approved pill that targets the oestrogen receptor in a different way, combined with another medicine. She feels anxious about side effects but hopeful that there is a new option designed for her type of cancer.

What happened

On 16 November 2026, the FDA approved giredestrant (Wilserdly), an oral oestrogen receptor antagonist, in combination with everolimus. It is for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease recurred during or after hormone-based adjuvant therapy, or progressed on at least one hormone-based treatment for advanced disease.

At the same time, the FDA authorised the FoundationOne Liquid CDx blood test as a companion diagnostic to identify ESR1 mutations.

The approval was reviewed under Project Orbis, which allows regulators in different countries to review cancer medicines together, in this case with Health Canada and Israel’s Ministry of Health. The FDA approved the application four weeks ahead of its target date.

10 key facts

  1. The FDA approved giredestrant (Wilserdly) on 16 November 2026.
  2. It is taken by mouth together with everolimus.
  3. It is for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer.
  4. It is for cancer that has progressed after hormone therapy.
  5. A blood test identifies ESR1 mutations.
  6. In the evERA trial, median progression-free survival was 10 months vs 5.5 months.
  7. The risk of cancer growth or death was reduced by 62%.
  8. 27% of patients had tumour shrinkage vs 14%.
  9. Common side effects include mouth sores, rash, fatigue and diarrhoea.
  10. Overall survival data are not yet mature.

The numbers at a glance

  • Approved: 16 November 2026
  • evERA trial: 373 adults, 207 with ESR1 mutations
  • Median progression-free survival (ESR1-mutated): 10 vs 5.5 months
  • Hazard ratio 0.38: 62% lower risk of progression or death
  • Objective response rate: 27% vs 14%
  • Approved 4 weeks ahead of the FDA goal date

What are ESR1 mutations?

About seven in ten breast cancers are hormone receptor-positive, meaning they grow in response to oestrogen. These are usually treated with hormone therapies that lower oestrogen or block its effects.

Over time, many advanced hormone receptor-positive cancers develop changes (mutations) in the ESR1 gene, which codes for the oestrogen receptor. These mutations can make the receptor active even without oestrogen, so the cancer becomes resistant to some hormone treatments, particularly aromatase inhibitors.

ESR1 mutations are often found after previous hormone therapy and can be detected with a blood test that looks for tumour DNA circulating in the blood, known as a liquid biopsy.

Why this matters

People with advanced breast cancer that no longer responds to hormone therapy need new options that delay progression while maintaining quality of life. Giredestrant is a pill, which can be more convenient than injected treatments.

The evERA results showed a substantial improvement in the time before the cancer grew in people with ESR1 mutations, nearly doubling it compared with standard options.

The approval reinforces the importance of testing for ESR1 mutations when advanced breast cancer progresses on hormone therapy.

What officials and experts said

The evERA trial ‘demonstrated a statistically significant improvement in progression-free survival’, according to the ASCO Post report on the approval.

What this means for you

  • If you have advanced ER-positive breast cancer that has progressed on hormone therapy, ask about ESR1 testing.
  • Ask your oncology team whether giredestrant is approved and available in your country.
  • Report mouth sores, rash, breathing changes or a slow heartbeat promptly.
  • Use effective contraception if advised, as the medicine can harm an unborn baby.
  • Keep attending regular scans and blood tests.
  • Seek support for emotional wellbeing during treatment.

What this means for nurses and health workers

Oncology nurses will support patients starting giredestrant and everolimus, especially in managing side effects.

  • Explain ESR1 testing and what results mean.
  • Teach mouth care to prevent and manage stomatitis.
  • Monitor for pneumonitis, slow heart rate and blood count changes.
  • Check blood glucose, electrolytes and kidney and liver tests.
  • Counsel on contraception.
  • Support adherence and quality of life.

The global picture

Breast cancer is the most commonly diagnosed cancer among women worldwide. Access to new targeted treatments and genomic testing varies greatly between countries. Project Orbis reviews may speed availability in Canada and Israel.

Side effects

The most common side effects reported with giredestrant plus everolimus, affecting at least one in five people, were mouth sores (stomatitis), rash, tiredness, diarrhoea, muscle and bone pain, lung inflammation (pneumonitis) and nausea. Blood tests may show low blood counts and changes in liver enzymes, salts and creatinine. The label warns about slow heart rate (bradycardia) and harm to an unborn baby.

What is everolimus?

Everolimus is an mTOR inhibitor, a medicine that blocks a pathway cancer cells use to grow. It is often combined with hormone therapy to overcome resistance.

What is progression-free survival?

Progression-free survival measures how long people live without their cancer growing or spreading. It is an important measure, but researchers also look at overall survival, which is not yet mature for this trial.

Liquid biopsy

A blood test can detect cancer DNA released into the blood, identifying mutations without a tissue biopsy.

Living with advanced breast cancer

Many people live for years with advanced breast cancer. Palliative care, emotional support and practical help improve quality of life alongside treatment.

Ask your team for written information and a contact number to call if you have concerns between appointments.

Other oral SERDs

Giredestrant belongs to a group of medicines called oral selective oestrogen receptor degraders or antagonists. Others have also been approved or are in development.

Questions to explore with your team

Every new treatment approval raises questions about whether it fits an individual’s situation. Factors include the type and extent of the cancer, previous treatments, ESR1 test results, other health conditions, side effect concerns, personal priorities and practical issues such as cost and access. Some people prefer oral treatments that can be taken at home, while others are more concerned about specific side effects such as mouth sores. Bringing a list of questions, a trusted companion and a notebook to appointments can help. Ask about clinical trials too, as these may offer access to new treatments. Breast cancer nurses and support organisations can help you prepare for these conversations and understand the information you receive.

Caring for your mouth during treatment

Mouth sores are one of the most common side effects when giredestrant is combined with everolimus. Many cancer teams recommend starting preventive mouth care from the first day of treatment. This may include rinsing several times a day with a prescribed alcohol-free mouthwash, brushing gently with a soft toothbrush, avoiding spicy, acidic or very hot foods, and drinking plenty of fluids. Report any soreness early, as prompt treatment can stop sores getting worse and prevent interruptions to cancer treatment. A dental check before starting can also help. Your oncology nurse can give you a personalised mouth care plan and advise on pain relief if sores develop, so that you can continue eating and drinking comfortably.

Myths and facts

Myth: All breast cancers are treated the same way.
Fact: Treatment depends on hormone receptors, HER2 and mutations.

Myth: ESR1 mutations are inherited.
Fact: They usually develop in the tumour during treatment.

Myth: Oral cancer treatments are weaker.
Fact: Many oral treatments are highly effective.

Myth: Advanced breast cancer can’t be treated.
Fact: Many treatments can control it for years.

Questions and answers

What is giredestrant?

An oral oestrogen receptor antagonist for breast cancer.

Who is it for?

Adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after hormone therapy.

Is it taken alone?

No, with everolimus.

How effective was it?

Median progression-free survival was 10 vs 5.5 months.

How is ESR1 tested?

With a blood test.

What are the side effects?

Mouth sores, rash, fatigue, diarrhoea and others.

Is it available outside the US?

It is being reviewed with Canada and Israel.

What happens next

Overall survival results from the evERA trial are expected later. Regulators in other countries are reviewing the medicine, and guidelines for advanced breast cancer may be updated. We will report further results as they are published.

Key takeaways

  • The FDA approved giredestrant (Wilserdly) on 16 November 2026.
  • It is for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer.
  • A blood test identifies ESR1 mutations.
  • The risk of cancer growth or death was reduced by 62%.
  • Common side effects include mouth sores, rash, fatigue and diarrhoea.
  • Overall survival data are not yet mature.

How we report health news

Nursing Media Network reports health news using official sources such as the World Health Organization, national public health agencies, medicines regulators and peer-reviewed research, which are linked at the end of each story. Figures in fast-moving stories, such as outbreaks, change quickly, so we state the date each number refers to. If you are reading this later, check the latest update from the official source before making decisions.

News reports describe what has happened across a population. They cannot tell you what is right for your own health. If a story raises questions about your treatment, symptoms or risk, speak to your nurse or healthcare provider before making any changes.

Staying informed without feeling overwhelmed

A constant stream of health headlines can leave people anxious or confused. It can help to choose one or two trusted sources and check them at set times, rather than scrolling throughout the day. Focus on what you can control, such as vaccinations, regular check-ups, healthy routines and knowing when to seek care. Talk about worries with family, friends or your nurse rather than keeping them to yourself, and take a break from news if it is affecting your sleep or mood. Being informed is useful; being overwhelmed is not.

Finding reliable health information

Health information online varies widely in quality. Prefer sources such as the World Health Organization, national health ministries, public health agencies, university hospitals and registered professional bodies. Be cautious with social media posts, miracle cures and products sold with promises that sound too good to be true.

If you read something that worries you or contradicts the advice you have been given, write it down and discuss it with your nurse or healthcare provider. They can explain how it applies to your own situation and help you separate evidence from rumour.

Questions to ask your nurse or healthcare provider

  • Should I be tested for an ESR1 mutation?
  • Is giredestrant an option for me?
  • What side effects should I expect?
  • How will we monitor my treatment?
  • Are there clinical trials I could join?
  • What support is available for living with advanced breast cancer?

But if hormone therapy has stopped working, are there still options?

Yes. Tests such as ESR1 can guide new targeted treatments, including newly approved oral options like giredestrant.

Your next step: If your advanced breast cancer has progressed on hormone therapy, ask your oncology team about ESR1 testing and new treatment options.

Related: Breast cancer · Fibroadenoma

Sources: The ASCO Post; FDA: novel drug approvals 2026.

Joshua Ibukunoluwa Adebanjo

Founder & Editor-in-Chief

Joshua Ibukunoluwa Adebanjo

RN, RM, RPHN, BNSc (Obafemi Awolowo University)

Joshua is a registered nurse, midwife and public health nurse with clinical experience at Obafemi Awolowo University Teaching Hospitals Complex. He founded Nursing Media Network to give nurses worldwide trustworthy news, career guidance and a stronger public voice, and leads its editorial direction.

Full profile · Editorial policy · joshuadebanjo.com

Health information on Nursing Media Network is for education and does not replace advice from your own nurse or healthcare provider.

Leave a Reply

Most read

Discover more from Nursing Media Network

Subscribe now to keep reading and get access to the full archive.

Continue reading